With an aim to enhance its service offering for particle technologies and drug product development and manufacture, Lonza has joined CMAC, an international research hub with a unique configuration of ...

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002 ... Additionally, the stable platform enabled the development of a robust, ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.